High-dose intravitreal ganciclovir and foscarnet for cytomegalovirus retinitis.
OBJECTIVE
To describe the chronic use of high doses of intravitreal ganciclovir, in combination with foscarnet, for the treatment of cytomegalovirus retinitis.


METHODS
A 31-year-old man with human immunodeficiency virus (HIV) infection and unilateral active cytomegalovirus retinitis was treated with escalating intravitreal injections of ganciclovir (up to 3.0 mg twice a week) in combination with foscarnet (up to 2.4 mg twice a week) over the course of approximately 1 year.


RESULTS
Complete regression of the retinitis was obtained with high doses of intravitreal ganciclovir and foscarnet. Visual acuity in the affected eye remained 20/20 throughout the course of therapy. No ganciclovir retinal toxicity was identified.


CONCLUSIONS
High doses of intravitreal ganciclovir in combination with foscarnet can be well tolerated and may be required to successfully control cytomegalovirus retinitis in some patients.
Velez
G
G
Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA. bruise-velez@erols.com
Roy
C E
CE
Whitcup
S M
SM
Chan
C C
CC
Robinson
M R
MR
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage*; D017726:Cytomegalovirus Retinitis / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D017245:Foscarnet / Q000008:administration & dosage*; D015774:Ganciclovir / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D016896:Treatment Outcome; D014792:Visual Acuity; D014822:Vitreous Body
D000998:Antiviral Agents; D017245:Foscarnet; D015774:Ganciclovir